{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Zeng L"],"pubmed_abstract":["<h4>Background</h4>Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC.<h4>Methods</h4>Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study.<h4>Results</h4>The tumor mutational burden"],"journal":["Frontiers in oncology"],"pagination":["796263"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8958003"],"repository":["biostudies-literature"],"pubmed_title":["Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy."],"pmcid":["PMC8958003"],"pubmed_authors":["Liu H","Liu K","Li J","Huang J","Zeng L","Cui W","Xia Q","Guan T","Cui S","Tang H","Wen J","Lei Z","Shao Y","Luo J","Huang X","Tian Y","Liao Q"],"additional_accession":[]},"is_claimable":false,"name":"Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy.","description":"<h4>Background</h4>Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC.<h4>Methods</h4>Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study.<h4>Results</h4>The tumor mutational burden","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-22T18:21:33.63Z","creation":"2025-04-06T02:23:54.648Z"},"accession":"S-EPMC8958003","cross_references":{"pubmed":["35350562"],"doi":["10.3389/fonc.2022.796263"]}}